|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
Testing use of predictive analytics to predict which COVID-19+ patients are at low risk for an adverse event (ICU transfer, intubation, mortality, hospice discharge, re-presentation to the ED, oxygen requirements exceeding nasal cannula at 6L/Min) in the next 96 hours
Description: Reduction in days from first low-risk score to dischargeMeasure: Reduction in days from first low-risk score to discharge Time: 96 Hours
Description: Reduction in LOS for green patients that have not been in the ICUMeasure: Reduction in length of stay (LOS) Time: 96 hours
Description: Reduction in GTD vs. LOS for all green patients discharged alive vs all patients discharged aliveMeasure: Reduction in GTD vs. LOS Time: 96 hours
Description: No change in 30 day re-ED presentation or hospital admission rate for cohortMeasure: No change in 30 day re-ED presentation or hospital admission rate for cohort Time: 96 hours
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports